According to Zhitong Finance App News, McPharmaceutical-B (02335.HK) issued an announcement. In the critical phase III clinical trial of the company's core product MT1013, all participants have completed the follow-up procedures stipulated in the study, treatment, and all trial plans, and have already left the team.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.